| Literature DB >> 26925955 |
Alon Kalron1, Ilia Fonkatz2, Lior Frid3, Hani Baransi4, Anat Achiron5,6.
Abstract
BACKGROUND: Multiple sclerosis (MS) is a multi-focal progressive disorder of the central nervous system often resulting in diverse clinical manifestations. Imbalance appears in most people with multiple sclerosis (PwMS). A popular balance training tool is virtual reality (VR) with several advantages including increased compliance and user satisfaction. Therefore, the aim of this pilot RCT (Trial registration number, date: ISRCTN14425615, 21/01/2016) was to examine the efficacy of a 6-week VR balance training program using the computer assisted rehabilitation environment (CAREN) system (Motek Medical BV, Amsterdam, Netherlands) on balance measures in PwMS. Results were compared with those of a conventional balance exercise group. Secondary aims included the impact of this program on the fear of falling.Entities:
Mesh:
Year: 2016 PMID: 26925955 PMCID: PMC4772661 DOI: 10.1186/s12984-016-0124-y
Source DB: PubMed Journal: J Neuroeng Rehabil ISSN: 1743-0003 Impact factor: 4.262
Fig. 1The CAREN Integrated Virtual Reality System
Fig. 2The virtual road scene projected on the system’s screen
Fig. 3The virtual road scene while intercepting moving targets
Fig. 4A flow chart of the study
Demographics and clinical characteristics of the study group
| Variable | Mean (S.D.) |
| |
|---|---|---|---|
| VR ( | Control ( | ||
| Age (years) | 47.3 (9.6) | 43.9 (10.6) | 0.433 |
| Gender | |||
| Male | 5 | 6 | --- |
| Female | 10 | 9 | --- |
| Disease duration (years) | 11.6 (7.7) | 10.4 (6.5) | 0.613 |
| Height (cm) | 167.4 (7.1) | 168.1 (8.8) | 0.459 |
| Body mass (kg) | 72.8 (11.4) | 70.8 (12.5) | 0.482 |
| EDSS | 4.5 (1.6) | 3.9 (1.3) | 0.327 |
| Pyramidal | 2.7 (0.9) | 2.5 (0.8) | 0.226 |
| Cerebellar | 1.8 (1.0) | 1.7 (0.8) | 0.241 |
| Sensory | 1.4 (1.0) | 1.2 (1.0) | 0.262 |
EDSS Expanded disability status scale
Comparison of the study outcome measures
| Parameters | VR group ( | Standardized exercise group ( |
|
| ||||
|---|---|---|---|---|---|---|---|---|
| Pre-intervention | Post-intervention | Mean difference | Pre-intervention | Post-intervention | Mean difference | |||
| Posturography- eyes open | ||||||||
| CoP path length (mm) | 345.3 (76.2) | 290.5 (105.3) | −54.8 (52.4) | 313.5 (89.5) | 272.9 (78.4) | −40.6 (32.9) | 5.278 (0.024)* | 1.569 (0.226) |
| Sway rate (mm/s) | 17.0 (6.3) | 13.0 (6.5) | −3.0 (3.4) | 16.1 (6.3) | 12.6 (4.4) | −3.5 (3.4) | 5.852 (0.035)* | 0.997 (0.232) |
| Ellipse sway area (mm2) | 309.0 (116.3) | 319.8 (130.5) | 10.8 (74.2) | 309.0 (116.3) | 319.8 (130.5) | 10.8 (74.2) | 0.754 (0.872) | 0.659 (0.624) |
| Pressure distribution difference (%) | 9.4 (7.4) | 9.5 (6.3) | 0.1 (6.1) | 9.4 (7.4) | 9.5 (6.3) | 0.1 (6.1) | 0.076 (0.984) | 0.085 (0.892) |
| Posturography- eyes closed | ||||||||
| CoP path length (mm) | 392.3 (112.3) | 333.1 (156.4) | −59.2 (98.0) | 376.1 (102.9) | 343.2 (146.9) | 32.9 (102.4) | 1.023 (0.189) | 0.067 (0.348) |
| Sway rate (mm/s) | 20.1 (15.3) | 18.4 (9.8) | −1.7 (7.7) | 22.4 (12.4) | 18.9 (11.8) | −3.5 (8.0) | 0.921 (0.239) | 0.910 (0.296) |
| Ellipse sway area (mm2) | 378.3 (109.5) | 342.5 (100.5) | −35.8 (94.2) | 363.3 (99.1) | 338.8 (109.4) | −24.5 (72.1) | 1.351 (0.137) | 0.004 (0.981) |
| Pressure distribution difference | 9.9 (7.9) | 10.3 (8.3) | 0.4 (5.1) | 9.6 (7.1) | 10.7 (6.3) | 1.1 (5.9) | 0.045 (0.887) | 0.019 (0.675) |
| Clinical balance tests | ||||||||
| FRT (cm) | 30.1 (5.0) | 34.8 (6.9) | 4.8 (4.1) | 27.6 (6.4) | 30.2 (4.9) | 2.6 (3.2) | 20.481 (0.001)* | 10.173 (0.009)* |
| BBT | 46.8 (9.6) | 47.9 (6.4) | 1.1 (4.2) | 43.3 (7.1) | 44.6 (4.9) | 1.3 (5.2) | 1.541 (0.215) | 1.794 (0.561) |
| FSST (s) | 16.2 (7.0) | 12.7 (6.4) | −4.5 (5.0) | 14.2 (7.1) | 11.7 (5.9) | −3.5 (6.1) | 9.011 (0.031)* | 1.250 (0.361) |
| FES-I questionnaire | 36.4 (9.7) | 29.4 (7.8) | −7.0 (4.3) | 32.9 (10.3) | 28.6 (5.8) | −4.3 (6.3) | 17.815 (0.023)* | 6.710 (0.021)* |
CoP Center of pressure, FRT Functional reach test, BBT Berg balance test, FSST Four step square test, FES-I Falls Efficacy Scale International
Values are expressed as mean (S.D). *P-Value <0.05